

**TDMS No.** 93025 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Tetralin

**CAS Number:** 119-64-2

**Date Report Requested:** 05/22/2008

**Time Report Requested:** 06:34:08

**First Dose M/F:** 06/23/03 / 06/23/03

**Lab:** BNW

**C Number:** C93025  
**Lock Date:** 03/22/2006  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.0.0

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

## HISTORICAL CONTROL STUDIES From October 2007 Report

### SAME ROUTE

- 96011-06 -- Cumene (INHALATION AIR)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

### ALL ROUTES

- 88138-04 -- Benzophenone (ORAL FEED)
- 99027-04 -- Chromium picolinate monohydrate (ORAL FEED)
- 05174-06 -- Cresols (ORAL FEED)
- 96011-06 -- Cumene (INHALATION AIR)
- 97003-08 -- 1,2-Dibromo-2,4-dicyanobutane (SKIN ETHANOL)
- 93020-08 -- Diisopropylcarbodiimide (SKIN ETHANOL)
- 88004-06 -- Divinylbenzene (INHALATION AIR)
- 88123-07 -- Formamide (GAVAGE WATER)
- 95011-06 -- 5-(Hydroxymethyl)-2-furfural (GAVAGE WATER)
- 88105-04 -- Isoeugenol (GAVAGE CORN OIL)
- 97006-02 -- Methyl isobutyl ketone (INHALATION AIR)
- 91005-08 -- Methylene blue trihydrate (GAVAGE METHYLCELLULOSE)
- 92012-06 -- 2-Methylimidazole (ORAL FEED)
- 92013-06 -- 4-Methylimidazole (ORAL FEED)
- 88006-04 -- alpha-Methylstyrene (INHALATION AIR)
- 99023-04 -- beta-Myrcene (GAVAGE CORN OIL)
- 97008-06 -- Propargyl alcohol (INHALATION AIR)
- 20114-06 -- Sodium dichromate dihydrate (VI) (ORAL WATER)
- 96001-06 -- Stoddard solvent (type IIC) (INHALATION AIR)

**TDMS No.** 93025 - 06

**Test Type:** CHRONIC

**Route:** RESPIRATORY EXPOSURE WHOLE BODY

**Species/Strain:** MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Tetralin

**CAS Number:** 119-64-2

**Date Report Requested:** 05/22/2008

**Time Report Requested:** 06:34:08

**First Dose M/F:** 06/23/03 / 06/23/03

**Lab:** BNW

**HISTORICAL CONTROL STUDIES  
From October 2007 Report**

05109-14 -- Triethanolamine (SKIN ACETONE)

96019-06 -- Water disinfection byproducts (Bromochloroacetic acid) (ORAL WATER)

96018-04 -- Water disinfection byproducts (Bromodichloromethane) (ORAL WATER)

96017-06 -- Water disinfection byproducts (Dibromoacetic acid) (ORAL WATER)

96015-06 -- Water disinfection byproducts (Dibromoacetonitrile) (ORAL WATER)

96010-04 -- Water disinfection byproducts (Sodium chlorate) (ORAL WATER)

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

**FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.  
IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.**

Adrenal Cortex  
Adrenal Medulla  
Bone Marrow  
Heart  
Islets, Pancreatic  
Kidney  
Liver  
Lung  
Ovary  
Pituitary Gland  
Spleen  
Thyroid Gland

TDMS No. 93025 - 06

Test Type: CHRONIC

Route: RESPIRATORY EXPOSURE WHOLE BODY

Species/Strain: MICE/B6C3F1

**P08: STATISTICAL ANALYSIS OF PRIMARY TUMORS**

Tetralin

CAS Number: 119-64-2

Date Report Requested: 05/22/2008

Time Report Requested: 06:34:08

First Dose M/F: 06/23/03 / 06/23/03

Lab: BNW

**SUMMARY OF STATISTICALLY SIGNIFICANT ( $P \leq .05$ ) RESULTS IN THE ANALYSIS OF Tetralin**

**MALE MICE**

**Organ**

Harderian Gland  
Islets, Pancreatic  
All Organs

**Morphology**

Carcinoma  
Adenoma  
Hemangiosarcoma or Hemangioma  
Benign Tumors  
Malignant and Benign Tumors

**FEMALE MICE**

**Organ**

Liver  
Lung  
  
Spleen  
All Organs

**Morphology**

Hepatocellular Carcinoma  
Alveolar/Bronchiolar Adenoma  
Alveolar/Bronchiolar Carcinoma  
Hemangiosarcoma  
Benign Tumors  
Malignant and Benign Tumors

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Adrenal Cortex  
Adenoma**

**TUMOR RATES**

OVERALL (a)	2/49 (4%)	0/49 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	2/44.17	0/44.56	1/45.72	2/44.37
POLY-3 PERCENT (g)	4.5%	0%	2.2%	4.5%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	1/38 (3%)	2/36 (6%)
FIRST INCIDENCE	593	---	729 (T)	729 (T)
HC TUMORS SAME RTE	11/297 (4%)			
HC TUMORS ALL RTES	74/1142 (7%)			

**STATISTICAL TESTS**

POLY 3	P=0.471	P=0.235N	P=0.488N	P=0.692N
POLY 1.5	P=0.473	P=0.235N	P=0.489N	P=0.690N
POLY 6	P=0.471	P=0.237N	P=0.487N	P=0.694
COCH-ARM / FISHERS	P=0.477	P=0.247N	P=0.492N	P=0.684N
MAX-ISO-POLY-3	P=0.416N	P=0.076N	P=0.273N	P=0.497N
HISTCONT SAME RTE	P=0.506	(e)	P=1.000	P=0.587
HISTCONT ALL RTES	P=0.490	(e)	P=1.000	P=1.000

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Bone Marrow  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/49 (2%)	0/50 (0%)	2/49 (4%)
POLY-3 RATE (b)	0/44.65	1/44.56	0/45.72	2/44.1
POLY-3 PERCENT (g)	0%	2.2%	0%	4.5%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	---	729 (T)	---	591
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	8/1142 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.139	P=0.500	(e)	P=0.234
POLY 1.5	P=0.138	P=0.499	(e)	P=0.233
POLY 6	P=0.140	P=0.499	(e)	P=0.237
COCH-ARM / FISHERS	P=0.137	P=0.495	(e)	P=0.242
MAX-ISO-POLY-3	P=0.076	P=0.159	(e)	P=0.075
HISTCONT SAME RTE	P=0.089	P=0.199	(e)	P=0.090
HISTCONT ALL RTES	P=0.053	P=0.190	(e)	P=0.034*

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	5/50 (10%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	2/45.12	5/45.51	4/45.99	1/44.37
POLY-3 PERCENT (g)	4.4%	11%	8.7%	2.3%
TERMINAL (d)	1/36 (3%)	4/35 (11%)	3/38 (8%)	1/36 (3%)
FIRST INCIDENCE	593	602	656	729 (T)
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	152/1149 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.281N	P=0.219	P=0.346	P=0.506N
POLY 1.5	P=0.278N	P=0.220	P=0.343	P=0.503N
POLY 6	P=0.284N	P=0.216	P=0.349	P=0.508N
COCH-ARM / FISHERS	P=0.273N	P=0.218	P=0.339	P=0.500N
MAX-ISO-POLY-3	P=0.222N	P=0.123	P=0.210	P=0.287N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	3/50 (6%)	3/50 (6%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	3/44.65	3/45.07	0/45.72	1/44.37
POLY-3 PERCENT (g)	6.7%	6.7%	0%	2.3%
TERMINAL (d)	3/36 (8%)	3/35 (9%)	0/38 (0%)	1/36 (3%)
FIRST INCIDENCE	729 (T)	729 (T)	---	729 (T)
HC TUMORS SAME RTE	11/300 (4%)			
HC TUMORS ALL RTES	30/1149 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.133N	P=0.658N	P=0.114N	P=0.307N
POLY 1.5	P=0.134N	P=0.658N	P=0.116N	P=0.307N
POLY 6	P=0.132N	P=0.661N	P=0.113N	P=0.307N
COCH-ARM / FISHERS	P=0.134N	P=0.661N	P=0.121N	P=0.309N
MAX-ISO-POLY-3	P=0.137N	P=0.495N	P=0.038N*	P=0.156N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Carcinoma or Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	5/50 (10%)	8/50 (16%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	5/45.12	8/45.51	4/45.99	2/44.37
POLY-3 PERCENT (g)	11.1%	17.6%	8.7%	4.5%
TERMINAL (d)	4/36 (11%)	7/35 (20%)	3/38 (8%)	2/36 (6%)
FIRST INCIDENCE	593	602	656	729 (T)
HC TUMORS SAME RTE	48/300 (16%)			
HC TUMORS ALL RTES	176/1149 (15%)			

**STATISTICAL TESTS**

POLY 3	P=0.092N	P=0.280	P=0.488N	P=0.223N
POLY 1.5	P=0.091N	P=0.281	P=0.492N	P=0.220N
POLY 6	P=0.092N	P=0.275	P=0.483N	P=0.225N
COCH-ARM / FISHERS	P=0.089N	P=0.277	P=0.500N	P=0.218N
MAX-ISO-POLY-3	P=0.104N	P=0.190	P=0.352N	P=0.126N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Islets, Pancreatic  
Adenoma**

**TUMOR RATES**

OVERALL (a)	2/49 (4%)	0/48 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.06	0/43.93	0/45.72	0/44.37
POLY-3 PERCENT (g)	4.5%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	618	---	---	---
HC TUMORS SAME RTE	3/295 (1%)			
HC TUMORS ALL RTES	11/1136 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.111N	P=0.238N	P=0.229N	P=0.235N
POLY 1.5	P=0.111N	P=0.239N	P=0.230N	P=0.234N
POLY 6	P=0.111N	P=0.238N	P=0.228N	P=0.236N
COCH-ARM / FISHERS	P=0.112N	P=0.253N	P=0.242N	P=0.242N
MAX-ISO-POLY-3	P=0.032N*	P=0.077N	P=0.075N	P=0.075N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Islets, Pancreatic  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	2/49 (4%)	0/48 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	2/44.06	0/43.93	1/45.72	0/44.37
POLY-3 PERCENT (g)	4.5%	0%	2.2%	0%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	1/38 (3%)	0/36 (0%)
FIRST INCIDENCE	618	---	729 (T)	---
HC TUMORS SAME RTE	4/295 (1%)			
HC TUMORS ALL RTES	12/1136 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.187N	P=0.238N	P=0.487N	P=0.235N
POLY 1.5	P=0.186N	P=0.239N	P=0.489N	P=0.234N
POLY 6	P=0.187N	P=0.238N	P=0.486N	P=0.236N
COCH-ARM / FISHERS	P=0.183N	P=0.253N	P=0.492N	P=0.242N
MAX-ISO-POLY-3	P=0.078N	P=0.077N	P=0.272N	P=0.075N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	1/49 (2%)	3/50 (6%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/44.13	3/45.21	0/45.72	1/44.84
POLY-3 PERCENT (g)	2.3%	6.6%	0%	2.2%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	592	705	---	591
HC TUMORS SAME RTE	10/299 (3%)			
HC TUMORS ALL RTES	30/1146 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.403N	P=0.314	P=0.493N	P=0.757N
POLY 1.5	P=0.403N	P=0.314	P=0.494N	P=0.757N
POLY 6	P=0.403N	P=0.310	P=0.492N	P=0.757N
COCH-ARM / FISHERS	P=0.404N	P=0.316	P=0.495N	P=0.747N
MAX-ISO-POLY-3	P=0.271N	P=0.162	P=0.157N	P=0.495N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Liver</b>				
<b>Hepatocellular Adenoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	33/49 (67%)	31/50 (62%)	35/50 (70%)	27/50 (54%)
POLY-3 RATE (b)	33/44.98	31/47.97	35/48.98	27/45.73
POLY-3 PERCENT (g)	73.4%	64.6%	71.5%	59%
TERMINAL (d)	29/36 (81%)	24/35 (69%)	26/38 (68%)	21/36 (58%)
FIRST INCIDENCE	516	454	493	591
HC TUMORS SAME RTE	141/299 (47%)			
HC TUMORS ALL RTES	544/1146 (48%)			

**STATISTICAL TESTS**

POLY 3	P=0.124N	P=0.239N	P=0.510N	P=0.102N
POLY 1.5	P=0.127N	P=0.284N	P=0.587N	P=0.112N
POLY 6	P=0.110N	P=0.200N	P=0.416N	P=0.087N
COCH-ARM / FISHERS	P=0.124N	P=0.365N	P=0.473	P=0.124N
MAX-ISO-POLY-3	P=0.112N	P=0.180N	P=0.417N	P=0.067N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hepatocellular Carcinoma**

**TUMOR RATES**

OVERALL (a)	11/49 (22%)	17/50 (34%)	14/50 (28%)	14/50 (28%)
POLY-3 RATE (b)	11/46.73	17/47.9	14/47.77	14/47.96
POLY-3 PERCENT (g)	23.5%	35.5%	29.3%	29.2%
TERMINAL (d)	5/36 (14%)	9/35 (26%)	8/38 (21%)	6/36 (17%)
FIRST INCIDENCE	422	454	593	478
HC TUMORS SAME RTE	74/299 (25%)			
HC TUMORS ALL RTES	317/1146 (28%)			

**STATISTICAL TESTS**

POLY 3	P=0.443	P=0.146	P=0.344	P=0.349
POLY 1.5	P=0.438	P=0.148	P=0.343	P=0.345
POLY 6	P=0.455	P=0.143	P=0.350	P=0.356
COCH-ARM / FISHERS	P=0.436	P=0.146	P=0.343	P=0.343
MAX-ISO-POLY-3	P=0.332	P=0.102	P=0.265	P=0.269
HISTCONT SAME RTE	P=0.396	P=0.111	P=0.342	P=0.348
HISTCONT ALL RTES	P=0.385	P=0.118	P=0.329	P=0.335

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	37/49 (76%)	40/50 (80%)	40/50 (80%)	35/50 (70%)
POLY-3 RATE (b)	37/46.96	40/49.17	40/49.86	35/48.16
POLY-3 PERCENT (g)	78.8%	81.4%	80.2%	72.7%
TERMINAL (d)	29/36 (81%)	28/35 (80%)	29/38 (76%)	25/36 (69%)
FIRST INCIDENCE	422	454	493	478
HC TUMORS SAME RTE	185/299 (62%)			
HC TUMORS ALL RTES	729/1146 (64%)			

**STATISTICAL TESTS**

POLY 3	P=0.222N	P=0.476	P=0.531	P=0.321N
POLY 1.5	P=0.233N	P=0.440	P=0.470	P=0.336N
POLY 6	P=0.200N	P=0.513	P=0.601N	P=0.295N
COCH-ARM / FISHERS	P=0.237N	P=0.384	P=0.384	P=0.349N
MAX-ISO-POLY-3	P=0.304N	P=0.374	P=0.430	P=0.242N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Liver  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	37/49 (76%)	40/50 (80%)	40/50 (80%)	35/50 (70%)
POLY-3 RATE (b)	37/46.96	40/49.17	40/49.86	35/48.16
POLY-3 PERCENT (g)	78.8%	81.4%	80.2%	72.7%
TERMINAL (d)	29/36 (81%)	28/35 (80%)	29/38 (76%)	25/36 (69%)
FIRST INCIDENCE	422	454	493	478
HC TUMORS SAME RTE	186/299 (62%)			
HC TUMORS ALL RTES	740/1146 (65%)			

**STATISTICAL TESTS**

POLY 3	P=0.222N	P=0.476	P=0.531	P=0.321N
POLY 1.5	P=0.233N	P=0.440	P=0.470	P=0.336N
POLY 6	P=0.200N	P=0.513	P=0.601N	P=0.295N
COCH-ARM / FISHERS	P=0.237N	P=0.384	P=0.384	P=0.349N
MAX-ISO-POLY-3	P=0.304N	P=0.374	P=0.430	P=0.242N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Lung  
Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	10/50 (20%)	6/50 (12%)	6/50 (12%)	8/50 (16%)
POLY-3 RATE (b)	10/45.93	6/45.16	6/45.86	8/45.15
POLY-3 PERCENT (g)	21.8%	13.3%	13.1%	17.7%
TERMINAL (d)	7/36 (19%)	5/35 (14%)	5/38 (13%)	7/36 (19%)
FIRST INCIDENCE	422	705	694	444
HC TUMORS SAME RTE	58/299 (19%)			
HC TUMORS ALL RTES	209/1148 (18%)			

**STATISTICAL TESTS**

POLY 3	P=0.426N	P=0.215N	P=0.205N	P=0.412N
POLY 1.5	P=0.425N	P=0.211N	P=0.206N	P=0.407N
POLY 6	P=0.425N	P=0.223N	P=0.204N	P=0.417N
COCH-ARM / FISHERS	P=0.420N	P=0.207N	P=0.207N	P=0.398N
MAX-ISO-POLY-3	P=0.295N	P=0.145N	P=0.136N	P=0.315N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung  
Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	11/50 (22%)	7/50 (14%)	12/50 (24%)	8/50 (16%)
POLY-3 RATE (b)	11/45.33	7/45.07	12/45.77	8/44.37
POLY-3 PERCENT (g)	24.3%	15.5%	26.2%	18%
TERMINAL (d)	8/36 (22%)	7/35 (20%)	11/38 (29%)	8/36 (22%)
FIRST INCIDENCE	618	729 (T)	716	729 (T)
HC TUMORS SAME RTE	38/299 (13%)			
HC TUMORS ALL RTES	115/1148 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.397N	P=0.218N	P=0.511	P=0.321N
POLY 1.5	P=0.391N	P=0.216N	P=0.508	P=0.314N
POLY 6	P=0.401N	P=0.229N	P=0.509	P=0.330N
COCH-ARM / FISHERS	P=0.380N	P=0.218N	P=0.500	P=0.306N
MAX-ISO-POLY-3	P=0.383N	P=0.149N	P=0.414	P=0.238N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	20/50 (40%)	13/50 (26%)	18/50 (36%)	14/50 (28%)
POLY-3 RATE (b)	20/46.6	13/45.16	18/45.91	14/45.15
POLY-3 PERCENT (g)	42.9%	28.8%	39.2%	31%
TERMINAL (d)	14/36 (39%)	12/35 (34%)	16/38 (42%)	13/36 (36%)
FIRST INCIDENCE	422	705	694	444
HC TUMORS SAME RTE	92/299 (31%)			
HC TUMORS ALL RTES	309/1148 (27%)			

**STATISTICAL TESTS**

POLY 3	P=0.230N	P=0.113N	P=0.440N	P=0.165N
POLY 1.5	P=0.224N	P=0.106N	P=0.430N	P=0.156N
POLY 6	P=0.236N	P=0.129N	P=0.454N	P=0.178N
COCH-ARM / FISHERS	P=0.214N	P=0.101N	P=0.418N	P=0.146N
MAX-ISO-POLY-3	P=0.187N	P=0.080N	P=0.358N	P=0.121N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Mammary Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.65	0/45.07	0/45.72	0/44.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	0/300 (0%)			
HC TUMORS ALL RTES	1/1149 (0%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Pituitary Gland: Pars Distalis or Unspecified Site  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/49 (2%)	0/48 (0%)	0/49 (0%)
POLY-3 RATE (b)	0/44.65	1/44.56	0/45.04	0/43.37
POLY-3 PERCENT (g)	0%	2.2%	0%	0%
TERMINAL (d)	0/36 (0%)	1/35 (3%)	0/38 (0%)	0/35 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
HC TUMORS SAME RTE	1/290 (0%)			
HC TUMORS ALL RTES	3/1119 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.564N	P=0.500	(e)	(e)
POLY 1.5	P=0.566N	P=0.499	(e)	(e)
POLY 6	P=0.563N	P=0.499	(e)	(e)
COCH-ARM / FISHERS	P=0.570N	P=0.495	(e)	(e)
MAX-ISO-POLY-3	P=0.397N	P=0.159	(e)	(e)
HISTCONT SAME RTE	(h)	(h)	(e)	(e)
HISTCONT ALL RTES	(h)	(h)	(e)	(e)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Skin  
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.65	1/45.07	0/45.72	0/44.37
POLY-3 PERCENT (g)	4.5%	2.2%	0%	0%
TERMINAL (d)	2/36 (6%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	14/1149 (1%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.100N	P=0.497N	P=0.232N	P=0.238N
POLY 1.5	P=0.100N	P=0.497N	P=0.234N	P=0.238N
POLY 6	P=0.099N	P=0.499N	P=0.230N	P=0.238N
COCH-ARM / FISHERS	P=0.101N	P=0.500N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.079N	P=0.279N	P=0.076N	P=0.077N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Skin  
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	2/44.65	1/45.07	0/45.72	0/44.37
POLY-3 PERCENT (g)	4.5%	2.2%	0%	0%
TERMINAL (d)	2/36 (6%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	---	---
HC TUMORS SAME RTE	7/300 (2%)			
HC TUMORS ALL RTES	11/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.100N	P=0.497N	P=0.232N	P=0.238N
POLY 1.5	P=0.100N	P=0.497N	P=0.234N	P=0.238N
POLY 6	P=0.099N	P=0.499N	P=0.230N	P=0.238N
COCH-ARM / FISHERS	P=0.101N	P=0.500N	P=0.247N	P=0.247N
MAX-ISO-POLY-3	P=0.079N	P=0.279N	P=0.076N	P=0.077N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Skin</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/44.9	1/45.07	1/45.84	1/44.47
POLY-3 PERCENT (g)	4.5%	2.2%	2.2%	2.3%
TERMINAL (d)	1/36 (3%)	1/35 (3%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	663	729 (T)	700	705
HC TUMORS SAME RTE	1/300 (0%)			
HC TUMORS ALL RTES	7/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.411N	P=0.499N	P=0.493N	P=0.503N
POLY 1.5	P=0.411N	P=0.498N	P=0.495N	P=0.502N
POLY 6	P=0.410N	P=0.503N	P=0.491N	P=0.504N
COCH-ARM / FISHERS	P=0.409N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.423N	P=0.280N	P=0.276N	P=0.284N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Spleen  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	1/49 (2%)	0/49 (0%)	0/49 (0%)	2/49 (4%)
POLY-3 RATE (b)	1/43.67	0/44.56	0/45.41	2/44.65
POLY-3 PERCENT (g)	2.3%	0%	0%	4.5%
TERMINAL (d)	1/36 (3%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	729 (T)	---	---	591
HC TUMORS SAME RTE	4/297 (1%)			
HC TUMORS ALL RTES	21/1136 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.247	P=0.496N	P=0.492N	P=0.508
POLY 1.5	P=0.246	P=0.497N	P=0.495N	P=0.504
POLY 6	P=0.249	P=0.496N	P=0.489N	P=0.513
COCH-ARM / FISHERS	P=0.246	P=0.500N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.142	P=0.158N	P=0.158N	P=0.289
HISTCONT SAME RTE	P=0.106	(e)	(e)	P=0.082
HISTCONT ALL RTES	P=0.163	(e)	(e)	P=0.175

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

**Stomach, Forestomach  
Squamous Cell Papilloma**

TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/44.65	0/45.07	0/45.72	1/44.37
POLY-3 PERCENT (g)	0%	0%	0%	2.3%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	1/36 (3%)
FIRST INCIDENCE	---	---	---	729 (T)
HC TUMORS SAME RTE	2/300 (1%)			
HC TUMORS ALL RTES	11/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.198	(e)	(e)	P=0.499
POLY 1.5	P=0.198	(e)	(e)	P=0.499
POLY 6	P=0.198	(e)	(e)	P=0.499
COCH-ARM / FISHERS	P=0.198	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.124	(e)	(e)	P=0.158
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	4/50 (8%)	5/50 (10%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	4/45.37	5/45.21	1/45.84	2/44.94
POLY-3 PERCENT (g)	8.8%	11.1%	2.2%	4.5%
TERMINAL (d)	2/36 (6%)	3/35 (9%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	592	705	700	591
HC TUMORS SAME RTE	16/300 (5%)			
HC TUMORS ALL RTES	67/1149 (6%)			

**STATISTICAL TESTS**

POLY 3	P=0.157N	P=0.498	P=0.175N	P=0.341N
POLY 1.5	P=0.158N	P=0.501	P=0.177N	P=0.340N
POLY 6	P=0.157N	P=0.489	P=0.175N	P=0.342N
COCH-ARM / FISHERS	P=0.157N	P=0.500	P=0.181N	P=0.339N
MAX-ISO-POLY-3	P=0.164N	P=0.361	P=0.083N	P=0.205N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**All Organs  
Hemangiosarcoma or Hemangioma**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	5/50 (10%)	5/50 (10%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	5/45.37	5/45.21	1/45.84	2/44.94
POLY-3 PERCENT (g)	11%	11.1%	2.2%	4.5%
TERMINAL (d)	3/36 (8%)	3/35 (9%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	592	705	700	591
HC TUMORS SAME RTE	19/300 (6%)			
HC TUMORS ALL RTES	76/1149 (7%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.095N	P=0.628	P=0.099N	P=0.220N
POLY 1.5	P=0.095N	P=0.629N	P=0.100N	P=0.219N
POLY 6	P=0.094N	P=0.620	P=0.098N	P=0.220N
COCH-ARM / FISHERS	P=0.095N	P=0.630N	P=0.102N	P=0.218N
MAX-ISO-POLY-3	P=0.123N	P=0.497	P=0.044N*	P=0.123N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Histiocytic Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/44.65	0/45.07	0/45.72	0/44.37
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/35 (0%)	0/38 (0%)	0/36 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	7/1149 (1%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**All Organs**  
**Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

---

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	2/44.65	1/45.07	4/45.77	2/44.37
POLY-3 PERCENT (g)	4.5%	2.2%	8.7%	4.5%
TERMINAL (d)	2/36 (6%)	1/35 (3%)	3/38 (8%)	2/36 (6%)
FIRST INCIDENCE	729 (T)	729 (T)	716	729 (T)
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	34/1149 (3%)			

**STATISTICAL TESTS**

---

POLY 3	P=0.471	P=0.497N	P=0.349	P=0.692
POLY 1.5	P=0.472	P=0.497N	P=0.345	P=0.692
POLY 6	P=0.473	P=0.499N	P=0.353	P=0.692
COCH-ARM / FISHERS	P=0.477	P=0.500N	P=0.339	P=0.691N
MAX-ISO-POLY-3	P=0.387	P=0.279N	P=0.212	P=0.497
HISTCONT SAME RTE	P=0.292	P=1.000	P=0.084	P=0.391
HISTCONT ALL RTES	P=0.225	P=1.000	P=0.051	P=0.424

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	42/50 (84%)	36/50 (72%)	38/50 (76%)	31/50 (62%)
POLY-3 RATE (b)	42/48.43	36/48.07	38/49.12	31/46.51
POLY-3 PERCENT (g)	86.7%	74.9%	77.4%	66.7%
TERMINAL (d)	32/36 (89%)	28/35 (80%)	28/38 (74%)	24/36 (67%)
FIRST INCIDENCE	422	454	493	444
HC TUMORS SAME RTE	200/300 (67%)			
HC TUMORS ALL RTES	753/1149 (66%)			

**STATISTICAL TESTS**

POLY 3	P=0.019N*	P=0.101N	P=0.168N	P=0.014N*
POLY 1.5	P=0.017N*	P=0.102N	P=0.188N	P=0.012N*
POLY 6	P=0.021N*	P=0.113N	P=0.148N	P=0.017N*
COCH-ARM / FISHERS	P=0.014N*	P=0.114N	P=0.227N	P=0.012N*
MAX-ISO-POLY-3	P=0.015N*	P=0.061N	P=0.109N	P=0.008N**
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	26/50 (52%)	27/50 (54%)	24/50 (48%)	26/50 (52%)
POLY-3 RATE (b)	26/48.14	27/48.83	24/47.82	26/48.83
POLY-3 PERCENT (g)	54%	55.3%	50.2%	53.3%
TERMINAL (d)	18/36 (50%)	15/35 (43%)	17/38 (45%)	16/36 (44%)
FIRST INCIDENCE	422	454	593	444
HC TUMORS SAME RTE	146/300 (49%)			
HC TUMORS ALL RTEs	582/1149 (51%)			

**STATISTICAL TESTS**

POLY 3	P=0.471N	P=0.531	P=0.432N	P=0.551N
POLY 1.5	P=0.479N	P=0.520	P=0.429N	P=0.562N
POLY 6	P=0.459N	P=0.542	P=0.430N	P=0.537N
COCH-ARM / FISHERS	P=0.490N	P=0.500	P=0.421N	P=0.579N
MAX-ISO-POLY-3	P=0.605N	P=0.449	P=0.353N	P=0.469N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTEs	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Males			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Malignant and Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	47/50 (94%)	46/50 (92%)	46/50 (92%)	42/50 (84%)
POLY-3 RATE (b)	47/49.14	46/50	46/50	42/49.02
POLY-3 PERCENT (g)	95.6%	92%	92%	85.7%
TERMINAL (d)	35/36 (97%)	31/35 (89%)	34/38 (90%)	30/36 (83%)
FIRST INCIDENCE	422	454	493	444
HC TUMORS SAME RTE	259/300 (86%)			
HC TUMORS ALL RTES	976/1149 (85%)			

**STATISTICAL TESTS**

POLY 3	P=0.057N	P=0.367N	P=0.367N	P=0.080N
POLY 1.5	P=0.054N	P=0.414N	P=0.414N	P=0.083N
POLY 6	P=0.063N	P=0.325N	P=0.325N	P=0.081N
COCH-ARM / FISHERS	P=0.056N	P=0.500N	P=0.500N	P=0.100N
MAX-ISO-POLY-3	P=0.059N	P=0.225N	P=0.225N	P=0.038N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Adrenal Cortex  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/40.7	1/45.29	1/48.78	2/48.62
POLY-3 PERCENT (g)	0%	2.2%	2.1%	4.1%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/42 (2%)	2/43 (5%)
FIRST INCIDENCE	---	731 (T)	731 (T)	731 (T)
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	5/1244 (0%)			

**STATISTICAL TESTS**

POLY 3	P=0.195	P=0.521	P=0.536	P=0.279
POLY 1.5	P=0.180	P=0.514	P=0.524	P=0.264
POLY 6	P=0.212	P=0.530	P=0.548	P=0.296
COCH-ARM / FISHERS	P=0.153	P=0.500	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.186	P=0.184	P=0.202	P=0.116
HISTCONT SAME RTE	P=0.051	P=0.226	P=0.235	P=0.063
HISTCONT ALL RTES	P<0.001**	P=0.101	P=0.105	P=0.007**

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Bone Marrow  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	2/49 (4%)
POLY-3 RATE (b)	1/40.7	0/45.29	0/48.78	2/47.9
POLY-3 PERCENT (g)	2.5%	0%	0%	4.2%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	---	---	705
HC TUMORS SAME RTE	2/297 (1%)			
HC TUMORS ALL RTES	7/1243 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.254	P=0.479N	P=0.464N	P=0.556
POLY 1.5	P=0.250	P=0.486N	P=0.476N	P=0.534
POLY 6	P=0.258	P=0.470N	P=0.452N	P=0.580
COCH-ARM / FISHERS	P=0.241	P=0.500N	P=0.500N	P=0.492
MAX-ISO-POLY-3	P=0.201	P=0.158N	P=0.158N	P=0.342
HISTCONT SAME RTE	P=0.130	(e)	(e)	P=0.116
HISTCONT ALL RTES	P=0.054	(e)	(e)	P=0.038*

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/40.7	1/45.29	1/48.78	1/48.62
POLY-3 PERCENT (g)	2.5%	2.2%	2.1%	2.1%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	1/42 (2%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)
HC TUMORS SAME RTE	29/300 (10%)			
HC TUMORS ALL RTES	128/1249 (10%)			

**STATISTICAL TESTS**

POLY 3	P=0.597N	P=0.736N	P=0.718N	P=0.719N
POLY 1.5	P=0.609N	P=0.745N	P=0.733N	P=0.734N
POLY 6	P=0.585N	P=0.726N	P=0.702N	P=0.703N
COCH-ARM / FISHERS	P=0.634	P=0.753N	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.693N	P=0.470N	P=0.452N	P=0.453N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	1/41.17	0/45.29	1/48.78	0/48.62
POLY-3 PERCENT (g)	2.4%	0%	2.1%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	1/42 (2%)	0/43 (0%)
FIRST INCIDENCE	592	---	731 (T)	---
HC TUMORS SAME RTE	10/300 (3%)			
HC TUMORS ALL RTES	33/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.392N	P=0.481N	P=0.721N	P=0.467N
POLY 1.5	P=0.396N	P=0.488N	P=0.735N	P=0.478N
POLY 6	P=0.388N	P=0.474N	P=0.707N	P=0.455N
COCH-ARM / FISHERS	P=0.405N	P=0.500N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.255N	P=0.158N	P=0.455N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Harderian Gland Carcinoma or Adenoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	2/41.17	1/45.29	2/48.78	1/48.62
POLY-3 PERCENT (g)	4.9%	2.2%	4.1%	2.1%
TERMINAL (d)	1/31 (3%)	1/38 (3%)	2/42 (5%)	1/43 (2%)
FIRST INCIDENCE	592	731 (T)	731 (T)	731 (T)
HC TUMORS SAME RTE	38/300 (13%)			
HC TUMORS ALL RTES	160/1249 (13%)			

**STATISTICAL TESTS**

POLY 3	P=0.401N	P=0.467N	P=0.631N	P=0.442N
POLY 1.5	P=0.415N	P=0.478N	P=0.653N	P=0.462N
POLY 6	P=0.387N	P=0.455N	P=0.609N	P=0.422N
COCH-ARM / FISHERS	P=0.444N	P=0.500N	P=0.691N	P=0.500N
MAX-ISO-POLY-3	P=0.405N	P=0.262N	P=0.435N	P=0.251N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Islets, Pancreatic  
Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.7	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	2/295 (1%)			
HC TUMORS ALL RTES	12/1228 (1%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Islets, Pancreatic  
Carcinoma or Adenoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/40.7	0/45.29	0/48.78	0/48.62
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME RTE	4/295 (1%)			
HC TUMORS ALL RTES	16/1228 (1%)			

**STATISTICAL TESTS**

POLY 3	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)
HISTCONT SAME RTE	(e)	(e)	(e)	(e)
HISTCONT ALL RTES	(e)	(e)	(e)	(e)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hemangiosarcoma**

**TUMOR RATES**

OVERALL (a)	2/50 (4%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/40.7	0/45.29	0/48.78	1/48.62
POLY-3 PERCENT (g)	4.9%	0%	0%	2.1%
TERMINAL (d)	2/31 (7%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	---	---	731 (T)
HC TUMORS SAME RTE	2/299 (1%)			
HC TUMORS ALL RTES	11/1245 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.475N	P=0.214N	P=0.200N	P=0.439N
POLY 1.5	P=0.469N	P=0.222N	P=0.212N	P=0.460N
POLY 6	P=0.484N	P=0.205N	P=0.187N	P=0.416N
COCH-ARM / FISHERS	P=0.461N	P=0.247N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.124N	P=0.075N	P=0.075N	P=0.249N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Liver  
Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	14/50 (28%)	16/50 (32%)	17/50 (34%)	22/50 (44%)
POLY-3 RATE (b)	14/41.44	16/46.1	17/49.16	22/48.66
POLY-3 PERCENT (g)	33.8%	34.7%	34.6%	45.2%
TERMINAL (d)	10/31 (32%)	12/38 (32%)	15/42 (36%)	21/43 (49%)
FIRST INCIDENCE	666	639	656	721
HC TUMORS SAME RTE	82/299 (27%)			
HC TUMORS ALL RTES	345/1245 (28%)			

**STATISTICAL TESTS**

POLY 3	P=0.129	P=0.553	P=0.556	P=0.187
POLY 1.5	P=0.098	P=0.503	P=0.479	P=0.138
POLY 6	P=0.162	P=0.572N	P=0.547N	P=0.243
COCH-ARM / FISHERS	P=0.051	P=0.414	P=0.333	P=0.072
MAX-ISO-POLY-3	P=0.208	P=0.464	P=0.470	P=0.151
HISTCONT SAME RTE	P=0.077	P=0.438	P=0.433	P=0.128
HISTCONT ALL RTES	P=0.238	P=0.537	P=0.535	P=0.179

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hepatocellular Carcinoma**

**TUMOR RATES**

OVERALL (a)	7/50 (14%)	5/50 (10%)	9/50 (18%)	2/50 (4%)
POLY-3 RATE (b)	7/40.7	5/45.7	9/49.35	2/48.7
POLY-3 PERCENT (g)	17.2%	10.9%	18.2%	4.1%
TERMINAL (d)	7/31 (23%)	3/38 (8%)	5/42 (12%)	0/43 (0%)
FIRST INCIDENCE	731 (T)	645	653	721
HC TUMORS SAME RTE	34/299 (11%)			
HC TUMORS ALL RTES	131/1245 (11%)			

**STATISTICAL TESTS**

POLY 3	P=0.057N	P=0.300N	P=0.558	P=0.044N*
POLY 1.5	P=0.071N	P=0.328N	P=0.499	P=0.055N
POLY 6	P=0.045N*	P=0.268N	P=0.594N	P=0.035N*
COCH-ARM / FISHERS	P=0.108N	P=0.380N	P=0.393	P=0.080N
MAX-ISO-POLY-3	P=0.070N	P=0.215N	P=0.452	P=0.029N*
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hepatocellular Carcinoma or Hepatocellular Adenoma**

**TUMOR RATES**

OVERALL (a)	20/50 (40%)	20/50 (40%)	23/50 (46%)	23/50 (46%)
POLY-3 RATE (b)	20/41.44	20/46.51	23/49.63	23/48.7
POLY-3 PERCENT (g)	48.3%	43%	46.3%	47.2%
TERMINAL (d)	16/31 (52%)	14/38 (37%)	18/42 (43%)	21/43 (49%)
FIRST INCIDENCE	666	639	653	721
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	419/1245 (34%)			

**STATISTICAL TESTS**

POLY 3	P=0.502	P=0.389N	P=0.511N	P=0.546N
POLY 1.5	P=0.422	P=0.460N	P=0.545	P=0.525
POLY 6	P=0.517N	P=0.311N	P=0.401N	P=0.451N
COCH-ARM / FISHERS	P=0.265	P=0.581N	P=0.343	P=0.343
MAX-ISO-POLY-3	P=0.634N	P=0.319N	P=0.431N	P=0.463N
HISTCONT SAME RTE	P=0.241	P=0.460	P=0.331	P=0.308
HISTCONT ALL RTES	P=0.398	P=0.507	P=0.431	P=0.418

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Liver  
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma**

**TUMOR RATES**

OVERALL (a)	20/50 (40%)	20/50 (40%)	23/50 (46%)	23/50 (46%)
POLY-3 RATE (b)	20/41.44	20/46.51	23/49.63	23/48.7
POLY-3 PERCENT (g)	48.3%	43%	46.3%	47.2%
TERMINAL (d)	16/31 (52%)	14/38 (37%)	18/42 (43%)	21/43 (49%)
FIRST INCIDENCE	666	639	653	721
HC TUMORS SAME RTE	104/299 (35%)			
HC TUMORS ALL RTES	421/1245 (34%)			

**STATISTICAL TESTS**

POLY 3	P=0.502	P=0.389N	P=0.511N	P=0.546N
POLY 1.5	P=0.422	P=0.460N	P=0.545	P=0.525
POLY 6	P=0.517N	P=0.311N	P=0.401N	P=0.451N
COCH-ARM / FISHERS	P=0.265	P=0.581N	P=0.343	P=0.343
MAX-ISO-POLY-3	P=0.634N	P=0.319N	P=0.431N	P=0.463N
HISTCONT SAME RTE	P=0.241	P=0.460	P=0.331	P=0.308
HISTCONT ALL RTES	P=0.407	P=0.511	P=0.435	P=0.421

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Lung  
Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	6/50 (12%)	1/50 (2%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	6/40.92	1/45.29	2/48.88	4/48.62
POLY-3 PERCENT (g)	14.7%	2.2%	4.1%	8.2%
TERMINAL (d)	5/31 (16%)	1/38 (3%)	1/42 (2%)	4/43 (9%)
FIRST INCIDENCE	674	731 (T)	704	731 (T)
HC TUMORS SAME RTE	15/300 (5%)			
HC TUMORS ALL RTES	65/1248 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.411N	P=0.041N*	P=0.084N	P=0.268N
POLY 1.5	P=0.420N	P=0.046N*	P=0.099N	P=0.301N
POLY 6	P=0.403N	P=0.036N*	P=0.071N	P=0.234N
COCH-ARM / FISHERS	P=0.442N	P=0.056N	P=0.134N	P=0.370N
MAX-ISO-POLY-3	P=0.079N	P=0.021N*	P=0.053N	P=0.189N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma**

**TUMOR RATES**

OVERALL (a)	0/50 (0%)	4/50 (8%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	0/40.7	4/45.29	2/48.88	2/48.62
POLY-3 PERCENT (g)	0%	8.8%	4.1%	4.1%
TERMINAL (d)	0/31 (0%)	4/38 (11%)	1/42 (2%)	2/43 (5%)
FIRST INCIDENCE	---	731 (T)	704	731 (T)
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	47/1248 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.515	P=0.075	P=0.280	P=0.279
POLY 1.5	P=0.476	P=0.070	P=0.265	P=0.264
POLY 6	P=0.556	P=0.081	P=0.297	P=0.296
COCH-ARM / FISHERS	P=0.404	P=0.059	P=0.247	P=0.247
MAX-ISO-POLY-3	P=0.195	P=0.031*	P=0.117	P=0.116
HISTCONT SAME RTE	P=0.234	P=0.034*	P=0.144	P=0.142
HISTCONT ALL RTES	P=0.224	P=0.032*	P=0.136	P=0.134

---



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

---

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

---

**Lung  
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma**

**TUMOR RATES**

OVERALL (a)	6/50 (12%)	5/50 (10%)	3/50 (6%)	6/50 (12%)
POLY-3 RATE (b)	6/40.92	5/45.29	3/48.88	6/48.62
POLY-3 PERCENT (g)	14.7%	11%	6.1%	12.3%
TERMINAL (d)	5/31 (16%)	5/38 (13%)	2/42 (5%)	6/43 (14%)
FIRST INCIDENCE	674	731 (T)	704	731 (T)
HC TUMORS SAME RTE	23/300 (8%)			
HC TUMORS ALL RTES	107/1248 (9%)			

**STATISTICAL TESTS**

POLY 3	P=0.481N	P=0.429N	P=0.163N	P=0.496N
POLY 1.5	P=0.508N	P=0.454N	P=0.188N	P=0.540N
POLY 6	P=0.456N	P=0.403N	P=0.140N	P=0.450N
COCH-ARM / FISHERS	P=0.563	P=0.500N	P=0.243N	P=0.620N
MAX-ISO-POLY-3	P=0.370N	P=0.317N	P=0.109N	P=0.383N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

---

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Mammary Gland Carcinoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	1/41.13	2/45.88	0/48.78	0/48.62
POLY-3 PERCENT (g)	2.4%	4.4%	0%	0%
TERMINAL (d)	0/31 (0%)	0/38 (0%)	0/42 (0%)	0/43 (0%)
FIRST INCIDENCE	607	586	---	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	16/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.164N	P=0.538	P=0.466N	P=0.467N
POLY 1.5	P=0.171N	P=0.524	P=0.478N	P=0.478N
POLY 6	P=0.157N	P=0.553	P=0.455N	P=0.455N
COCH-ARM / FISHERS	P=0.188N	P=0.500	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.194N	P=0.322	P=0.158N	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Ovary</b>				
<b>Cystadenoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	2/50 (4%)	3/50 (6%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	2/40.7	3/45.39	1/48.78	1/47.8
POLY-3 PERCENT (g)	4.9%	6.6%	2.1%	2.1%
TERMINAL (d)	2/31 (7%)	2/38 (5%)	1/42 (2%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	704	731 (T)	731 (T)
HC TUMORS SAME RTE	17/291 (6%)			
HC TUMORS ALL RTES	46/1221 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.236N	P=0.550	P=0.437N	P=0.444N
POLY 1.5	P=0.252N	P=0.532	P=0.459N	P=0.466N
POLY 6	P=0.220N	P=0.570	P=0.416N	P=0.421N
COCH-ARM / FISHERS	P=0.285N	P=0.500	P=0.500N	P=0.508N
MAX-ISO-POLY-3	P=0.332N	P=0.375	P=0.249N	P=0.253N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Pituitary Gland: Pars Distalis or Unspecified Site  
Adenoma**

**TUMOR RATES**

OVERALL (a)	6/49 (12%)	4/50 (8%)	8/50 (16%)	7/50 (14%)
POLY-3 RATE (b)	6/39.99	4/45.45	8/48.78	7/48.73
POLY-3 PERCENT (g)	15%	8.8%	16.4%	14.4%
TERMINAL (d)	4/30 (13%)	3/38 (8%)	8/42 (19%)	6/43 (14%)
FIRST INCIDENCE	674	690	731 (T)	705
HC TUMORS SAME RTE	41/294 (14%)			
HC TUMORS ALL RTES	97/1216 (8%)			

**STATISTICAL TESTS**

POLY 3	P=0.447	P=0.291N	P=0.544	P=0.585N
POLY 1.5	P=0.407	P=0.314N	P=0.496	P=0.603
POLY 6	P=0.488	P=0.268N	P=0.591	P=0.536N
COCH-ARM / FISHERS	P=0.330	P=0.357N	P=0.403	P=0.516
MAX-ISO-POLY-3	P=0.519	P=0.202N	P=0.433	P=0.468N
HISTCONT SAME RTE	P=0.625	P=1.000	P=0.561	P=1.000
HISTCONT ALL RTES	P=0.148	P=0.628	P=0.187	P=0.279

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Skin  
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/41.28	2/45.83	0/48.78	1/48.62
POLY-3 PERCENT (g)	2.4%	4.4%	0%	2.1%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	549	563	---	731 (T)
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1249 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.465N	P=0.536	P=0.467N	P=0.723N
POLY 1.5	P=0.476N	P=0.524	P=0.478N	P=0.736N
POLY 6	P=0.454N	P=0.551	P=0.456N	P=0.708N
COCH-ARM / FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.386N	P=0.320	P=0.158N	P=0.456N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**Skin  
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma**

TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/41.28	2/45.83	0/48.78	1/48.62
POLY-3 PERCENT (g)	2.4%	4.4%	0%	2.1%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	549	563	---	731 (T)
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	53/1249 (4%)			

**STATISTICAL TESTS**

POLY 3	P=0.465N	P=0.536	P=0.467N	P=0.723N
POLY 1.5	P=0.476N	P=0.524	P=0.478N	P=0.736N
POLY 6	P=0.454N	P=0.551	P=0.456N	P=0.708N
COCH-ARM / FISHERS	P=0.500N	P=0.500	P=0.500N	P=0.753N
MAX-ISO-POLY-3	P=0.386N	P=0.320	P=0.158N	P=0.456N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Skin</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/40.7	1/45.29	1/48.78	0/48.62
POLY-3 PERCENT (g)	0%	2.2%	2.1%	0%
TERMINAL (d)	0/31 (0%)	1/38 (3%)	1/42 (2%)	0/43 (0%)
FIRST INCIDENCE	---	731 (T)	731 (T)	---
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	17/1249 (1%)			

**STATISTICAL TESTS**

POLY 3	P=0.544N	P=0.521	P=0.536	(e)
POLY 1.5	P=0.561N	P=0.514	P=0.524	(e)
POLY 6	P=0.525N	P=0.530	P=0.548	(e)
COCH-ARM / FISHERS	P=0.595N	P=0.500	P=0.500	(e)
MAX-ISO-POLY-3	P=0.439N	P=0.184	P=0.202	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Spleen Hemangiosarcoma</b>				
<b>TUMOR RATES</b>				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	1/40.7	0/45.29	1/48.78	4/48.73
POLY-3 PERCENT (g)	2.5%	0%	2.1%	8.2%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	1/42 (2%)	3/43 (7%)
FIRST INCIDENCE	731 (T)	---	731 (T)	705
HC TUMORS SAME RTE	3/297 (1%)			
HC TUMORS ALL RTES	24/1230 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.041*	P=0.479N	P=0.718N	P=0.239
POLY 1.5	P=0.038*	P=0.486N	P=0.733N	P=0.217
POLY 6	P=0.044*	P=0.470N	P=0.702N	P=0.265
COCH-ARM / FISHERS	P=0.034*	P=0.500N	P=0.753N	P=0.181
MAX-ISO-POLY-3	P=0.064	P=0.158N	P=0.452N	P=0.141
HISTCONT SAME RTE	P=0.016*	(e)	P=0.349	P=0.026*
HISTCONT ALL RTES	P=0.062	(e)	P=1.000	P=0.044*



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Stomach, Forestomach Squamous Cell Papilloma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/40.7	2/45.29	1/48.78	1/48.62
POLY-3 PERCENT (g)	2.5%	4.4%	2.1%	2.1%
TERMINAL (d)	1/31 (3%)	2/38 (5%)	1/42 (2%)	1/43 (2%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)
HC TUMORS SAME RTE	3/300 (1%)			
HC TUMORS ALL RTES	20/1249 (2%)			

**STATISTICAL TESTS**

POLY 3	P=0.476N	P=0.537	P=0.718N	P=0.719N
POLY 1.5	P=0.494N	P=0.524	P=0.733N	P=0.734N
POLY 6	P=0.458N	P=0.552	P=0.702N	P=0.703N
COCH-ARM / FISHERS	P=0.531N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.560N	P=0.321	P=0.452N	P=0.453N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Uterus</b>				
<b>Polyp Stromal</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	1/40.7	3/45.29	4/49.06	0/48.62
POLY-3 PERCENT (g)	2.5%	6.6%	8.2%	0%
TERMINAL (d)	1/31 (3%)	3/38 (8%)	3/42 (7%)	0/43 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	656	---
HC TUMORS SAME RTE	14/300 (5%)			
HC TUMORS ALL RTES	33/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.224N	P=0.344	P=0.241	P=0.465N
POLY 1.5	P=0.253N	P=0.330	P=0.218	P=0.477N
POLY 6	P=0.196N	P=0.360	P=0.267	P=0.452N
COCH-ARM / FISHERS	P=0.313N	P=0.309	P=0.181	P=0.500N
MAX-ISO-POLY-3	P=0.172N	P=0.194	P=0.143	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>Uterus</b>				
<b>Sarcoma Stromal or Polyp Stromal</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	1/50 (2%)	4/50 (8%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	1/40.7	4/45.29	4/49.06	0/48.62
POLY-3 PERCENT (g)	2.5%	8.8%	8.2%	0%
TERMINAL (d)	1/31 (3%)	4/38 (11%)	3/42 (7%)	0/43 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	656	---
HC TUMORS SAME RTE	16/300 (5%)			
HC TUMORS ALL RTES	40/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.175N	P=0.213	P=0.241	P=0.465N
POLY 1.5	P=0.203N	P=0.200	P=0.218	P=0.477N
POLY 6	P=0.149N	P=0.227	P=0.267	P=0.452N
COCH-ARM / FISHERS	P=0.263N	P=0.181	P=0.181	P=0.500N
MAX-ISO-POLY-3	P=0.148N	P=0.116	P=0.143	P=0.158N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Hemangiosarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	2/40.7	2/45.39	2/48.88	4/48.73
POLY-3 PERCENT (g)	4.9%	4.4%	4.1%	8.2%
TERMINAL (d)	2/31 (7%)	1/38 (3%)	1/42 (2%)	3/43 (7%)
FIRST INCIDENCE	731 (T)	704	704	705
HC TUMORS SAME RTE	12/300 (4%)			
HC TUMORS ALL RTES	60/1249 (5%)			

**STATISTICAL TESTS**

POLY 3	P=0.279	P=0.654N	P=0.626N	P=0.423
POLY 1.5	P=0.260	P=0.668N	P=0.650N	P=0.393
POLY 6	P=0.301	P=0.637N	P=0.600N	P=0.458
COCH-ARM / FISHERS	P=0.221	P=0.691N	P=0.691N	P=0.339
MAX-ISO-POLY-3	P=0.391	P=0.457N	P=0.431N	P=0.287
HISTCONT SAME RTE	P=0.215	P=1.000	P=1.000	P=0.176
HISTCONT ALL RTES	P=0.454	P=1.000	P=1.000	P=0.327

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**All Organs  
Hemangiosarcoma or Hemangioma**

TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	5/50 (10%)
POLY-3 RATE (b)	2/40.7	2/45.39	2/48.88	5/48.73
POLY-3 PERCENT (g)	4.9%	4.4%	4.1%	10.3%
TERMINAL (d)	2/31 (7%)	1/38 (3%)	1/42 (2%)	4/43 (9%)
FIRST INCIDENCE	731 (T)	704	704	705
HC TUMORS SAME RTE	15/300 (5%)			
HC TUMORS ALL RTES	79/1249 (6%)			

**STATISTICAL TESTS**

POLY 3	P=0.153	P=0.654N	P=0.626N	P=0.296
POLY 1.5	P=0.139	P=0.668N	P=0.650N	P=0.267
POLY 6	P=0.167	P=0.637N	P=0.600N	P=0.330
COCH-ARM / FISHERS	P=0.114	P=0.691N	P=0.691N	P=0.218
MAX-ISO-POLY-3	P=0.241	P=0.457N	P=0.431N	P=0.197
HISTCONT SAME RTE	P=0.164	P=1.000	P=1.000	P=0.149
HISTCONT ALL RTES	P=0.277	P=1.000	P=1.000	P=0.237

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Histiocytic Sarcoma</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/40.8	1/46.22	1/48.94	1/48.62
POLY-3 PERCENT (g)	4.9%	2.2%	2%	2.1%
TERMINAL (d)	1/31 (3%)	0/38 (0%)	0/42 (0%)	1/43 (2%)
FIRST INCIDENCE	705	298	690	731 (T)
HC TUMORS SAME RTE	8/300 (3%)			
HC TUMORS ALL RTES	31/1249 (3%)			

**STATISTICAL TESTS**

POLY 3	P=0.384N	P=0.457N	P=0.437N	P=0.439N
POLY 1.5	P=0.392N	P=0.471N	P=0.459N	P=0.460N
POLY 6	P=0.377N	P=0.442N	P=0.415N	P=0.418N
COCH-ARM / FISHERS	P=0.409N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.371N	P=0.257N	P=0.249N	P=0.250N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM

**All Organs**  
**Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type**

TUMOR RATES	#	#	#	#
OVERALL (a)	12/50 (24%)	12/50 (24%)	10/50 (20%)	12/50 (24%)
POLY-3 RATE (b)	12/41.13	12/46.53	10/49.23	12/49.21
POLY-3 PERCENT (g)	29.2%	25.8%	20.3%	24.4%
TERMINAL (d)	10/31 (32%)	8/38 (21%)	7/42 (17%)	9/43 (21%)
FIRST INCIDENCE	673	514	656	648
HC TUMORS SAME RTE	64/300 (21%)			
HC TUMORS ALL RTES	284/1249 (23%)			

**STATISTICAL TESTS**

POLY 3	P=0.362N	P=0.455N	P=0.234N	P=0.393N
POLY 1.5	P=0.414N	P=0.505N	P=0.289N	P=0.463N
POLY 6	P=0.312N	P=0.399N	P=0.185N	P=0.322N
COCH-ARM / FISHERS	P=0.523N	P=0.592N	P=0.405N	P=0.592N
MAX-ISO-POLY-3	P=0.404N	P=0.368N	P=0.186N	P=0.320N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	24/50 (48%)	27/50 (54%)	26/50 (52%)	34/50 (68%)
POLY-3 RATE (b)	24/42.44	27/46.14	26/49.27	34/48.8
POLY-3 PERCENT (g)	56.6%	58.5%	52.8%	69.7%
TERMINAL (d)	18/31 (58%)	22/38 (58%)	23/42 (55%)	31/43 (72%)
FIRST INCIDENCE	432	639	656	705
HC TUMORS SAME RTE	170/300 (57%)			
HC TUMORS ALL RTES	644/1249 (52%)			

**STATISTICAL TESTS**

POLY 3	P=0.106	P=0.511	P=0.439N	P=0.134
POLY 1.5	P=0.071	P=0.449	P=0.542N	P=0.086
POLY 6	P=0.146	P=0.583	P=0.343N	P=0.200
COCH-ARM / FISHERS	P=0.029*	P=0.345	P=0.421	P=0.034*
MAX-ISO-POLY-3	P=0.165	P=0.425	P=0.366N	P=0.105
HISTCONT SAME RTE	P=0.198	P=0.551	P=1.000	P=0.129
HISTCONT ALL RTES	P=0.189	P=0.538	P=1.000	P=0.121



**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Malignant Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	27/50 (54%)	25/50 (50%)	23/50 (46%)	23/50 (46%)
POLY-3 RATE (b)	27/44.21	25/49.01	23/50	23/49.38
POLY-3 PERCENT (g)	61.1%	51%	46%	46.6%
TERMINAL (d)	18/31 (58%)	15/38 (40%)	15/42 (36%)	17/43 (40%)
FIRST INCIDENCE	432	298	653	648
HC TUMORS SAME RTE	149/300 (50%)			
HC TUMORS ALL RTES	629/1249 (50%)			

**STATISTICAL TESTS**

POLY 3	P=0.122N	P=0.220N	P=0.103N	P=0.114N
POLY 1.5	P=0.151N	P=0.278N	P=0.146N	P=0.155N
POLY 6	P=0.101N	P=0.172N	P=0.072N	P=0.084N
COCH-ARM / FISHERS	P=0.237N	P=0.421N	P=0.274N	P=0.274N
MAX-ISO-POLY-3	P=0.144N	P=0.175N	P=0.082N	P=0.090N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)

**STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)  
TERMINAL SACRIFICE AT 105 WEEKS**

DOSE	Females			
	CONTROL	30 PPM	60 PPM	120 PPM
<b>All Organs</b>				
<b>Malignant and Benign Tumors</b>				
<b>TUMOR RATES</b>	#	#	#	#
OVERALL (a)	40/50 (80%)	38/50 (76%)	38/50 (76%)	43/50 (86%)
POLY-3 RATE (b)	40/44.71	38/49.17	38/50	43/49.38
POLY-3 PERCENT (g)	89.5%	77.3%	76%	87.1%
TERMINAL (d)	28/31 (90%)	27/38 (71%)	30/42 (71%)	37/43 (86%)
FIRST INCIDENCE	432	298	653	648
HC TUMORS SAME RTE	240/300 (80%)			
HC TUMORS ALL RTES	939/1249 (75%)			

**STATISTICAL TESTS**

POLY 3	P=0.484	P=0.089N	P=0.067N	P=0.483N
POLY 1.5	P=0.399	P=0.161N	P=0.136N	P=0.619
POLY 6	P=0.545	P=0.051N	P=0.035N*	P=0.362N
COCH-ARM / FISHERS	P=0.212	P=0.405N	P=0.405N	P=0.298
MAX-ISO-POLY-3	P=0.204N	P=0.059N	P=0.046N*	P=0.358N
HISTCONT SAME RTE	P=0.392	P=1.000	P=1.000	P=0.313
HISTCONT ALL RTES	P=0.407	P=0.629	P=1.000	P=0.367

**LEGEND**

- (a) Number of tumor-bearing animals/number of animals examined at site.
  - (b) Number of tumor-bearing animals/Poly-3 number
  - (d) Observed incidence at terminal kill.
  - (e) Value of Statistic cannot be computed.
  - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
  - (g) Poly-3 adjusted lifetime tumor incidence.
  - (h) Value of Historical Controls statistic is only calculated when Poly-3 trend is positive and when there is more than one tumor in the treatment groups.
  - (I) Interim sacrifice
  - (T) Terminal sacrifice
  - # Tumor rates based on numbers of animals necropsied.
  - \* To the right of any statistical result, indicates significance at (P<=0.05).
  - \*\* To the right of any statistical result, indicates significance at (P<=0.01).
  - N Indicates a negative trend for all tests
- The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

\*\*\* END OF REPORT \*\*\*